Bad Drug List
Home / Bad Drugs / Tasmar

Tasmar

Tasmar is used with a Parkinson medication to treat Parkinson's disease. First approved in January 1998, about ten months on the market Tasmar warnings were issued and a boxed warning was added to Tasmar product labeling. Physicians prescribing Tasmar was advised about reports of a new finding of fatal liver injury associated with the use of Tasmar. The adverse Tasmar effects led the manufacturer and the FDA to recommend significant changes in how Tasmar is used, reserved only for patients who do not have severe movement abnormalities and who do not respond to or who are not appropriate candidates for alternate treatments.

At the time of the Tasmar warning, around 60,000 patients had used Tasmar worldwide. The Tasmar boxed warning advised doctors to increase liver monitoring for every two weeks when a prescriber decides a patient should be treated with Tasmar. Patients were advised to self-monitor themselves while on Tasmar for signs of liver disease, including jaundice, fatigue, and loss of appetite. In addition, patients that fail to show a substantial clinical benefit in the initial three weeks of Tasmar treatment were advised to be withdrawn from the drug.

Abruptly discontinuing the use of Tasmar or having a reduction in dose can also lead to serious Tasmar complications. If you would like more information on Tasmar contact us to confer with a Tasmar attorney.

MedLine Plus Drug Information - Guide to prescription and over-the-counter medications provided by the United States Pharmacopeia.

Tasmar.com - Official TASMAR® website designed as a central resource to provide you with information about TASMAR®, a prescription medication for certain patients with Parkinson's disease.